George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc
Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRocView Video
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors
Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investorsView Video

Latest Share Chat

Inovio Pharmaceuticals's Covid-19 vaccine triggers immune response

Tue, 30th Jun 2020 18:34

(Sharecast News) - Inovio Pharmaceuticals's experimental vaccine against the novel coronavirus was found to be safe in an early stage clinical trial and successfully induced an immune response in the majority of participants in the test.
Despite the results of the trial, as of 1803 BST shares of Inovio were slumping by 17.51% to $26.14 after some analysts sounded a cautious note on the results.

"We'd like to see data on these measures separately and broken out by dose before drawing too many conclusions," Piper Sandler analyst, Christopher Raymond, said.

The vaccine achieved immune responses - measured in the form of binding antibodies and T-cells - in 34 of 36 healthy volunteers participating in the trial, with full data set to be published in a peer-reviewed medical journal later on.

Admittedly however, the stock's price had more than doubled over the preceding seven sessions.

And for the biotech outfit's boss, Joseph Kim, the trial had been a success, Reuters reported.

Kim reportedly also claimed that his company's vaccine was likely the safest vaccine from among the various platforms being used against Covid-19.

A mid-to-late stage trial to evaluate the efficacy of the vaccine in summer.

Earlier, America's main regulatory body, the Food&Drug Administration had said that for a coronavirus vaccine to be deemed effective it would have to be able to either protect from infection or lower the severity of symptoms in at least half of those innoculated with it.

Inovio's vaccine was one of 17 being developed as part of the Trump administration's 'Warp Speed' programme.

Related Shares

More News
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the...

27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downt...

27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the w...

27 Mar 2024 08:02

LONDON BRIEFING: Diploma makes buy; Astra wins Japan drug approvals

(Alliance News) - Stocks in London opened in a muted fashion on Wednesday, with some unease lingering in equity markets ahead of a US inflation readin...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.